M-EDG's
Florida-Israel
Biomedical Initiative U.S. Commercialization for Israel's Biomedical Products
The FL-IBI provides a very well-suited marketing and distribution vehicle for the U.S. commercialization of Israel?omedical devices and products.* The main benefits to the Israeli biomedical companies seeking U.S. distribution relates to M-EDG??Equity-based Business Model?an>, which provides significant equity/ownership rather than simply a royalty under a conventional licensing agreement.
The main benefits to the
Israeli companies and their owners are:
-
Significantly greater participation in successful U.S. commercialization
-
From 20 to 30 times greater ROI for equity interests in Israeli biomedical companies
-
Post-commercialization Israeli majority-ownership potential
-
Increased U.S. recognition of Israel?eeminent biomedical product development expertise.
*
, the parent of the Florida--Israel
Biomedical Initiative, possesses well over 200 man-years of
hands-on and senior management responsibility for these dozen-plus
functional areas.
CLICK HERE
to read a list of
incredible scientific and technology breakthroughs
that were developed by and in the nation of Israel.
Israel
101
is produced by Stand
With Us, and provides an excellent introduction and historical
perspective to many of the issues facing Israel and the world.
NOTE: Clicking
the Israel 101 link will open a new window. M-EDG
is not responsible for the content of external websites.
